Literature DB >> 22498253

CD95 signaling in colorectal cancer.

Frederik J H Hoogwater1, Ernst J A Steller, B Florien Westendorp, Inne H M Borel Rinkes, Onno Kranenburg.   

Abstract

CD95 and its ligand (CD95L) are widely expressed in colorectal tumors, but their role in shaping tumor behavior is unclear. CD95 activation on tumor cells can lead to apoptosis, while CD95L attracts neutrophils, suggesting a function in tumor suppression. However, CD95 can also promote tumorigenesis, at least in part by activating non-apoptotic signaling pathways that stimulate tumor cell proliferation, invasion and survival. In addition, CD95 signaling in stromal cells and tumor-infiltrating inflammatory cells has to be taken into account when addressing the function of CD95 and its ligand in colorectal tumor biology. We present a model in which the tumor-suppressing and tumor-promoting activities of CD95/CD95L together determine colorectal tumor behavior. We also discuss how these multiple activities are changing our view of CD95 and CD95L as potential therapeutic targets in the treatment of colorectal cancer. We conclude that locking CD95 in apoptosis-mode may be a more promising anti-cancer strategy than simply inhibiting or stimulating CD95.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22498253     DOI: 10.1016/j.bbcan.2012.03.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.

Authors:  Bruno Christian Koehler; Dirk Jäger; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

2.  Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas stability.

Authors:  A Rossin; J Durivault; T Chakhtoura-Feghali; N Lounnas; L Gagnoux-Palacios; A-O Hueber
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

Review 3.  Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors.

Authors:  Gael Galli; Pierre Vacher; Bernhard Ryffel; Patrick Blanco; Patrick Legembre
Journal:  Cells       Date:  2022-04-24       Impact factor: 7.666

4.  Mice lacking functional CD95-ligand display reduced proliferation of the intestinal epithelium without gross homeostatic alterations.

Authors:  Kari Trumpi; Ernst J A Steller; Wendy W de Leng; Daniëlle A Raats; Isaäc J Nijman; Folkert H M Morsink; Inne H M Borel Rinkes; Onno Kranenburg
Journal:  Med Mol Morphol       Date:  2015-12-23       Impact factor: 2.309

5.  Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation.

Authors:  Qiuyan Liu; Qinchun Tan; Yuanyuan Zheng; Kun Chen; Cheng Qian; Nan Li; Qingqing Wang; Xuetao Cao
Journal:  J Biol Chem       Date:  2014-03-13       Impact factor: 5.157

6.  FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin.

Authors:  Shizhi Wang; Shenshen Wu; Qingtao Meng; Xiaobo Li; Jinchun Zhang; Rui Chen; Meilin Wang
Journal:  Sci Rep       Date:  2016-01-13       Impact factor: 4.379

7.  An Evolution-Guided Analysis Reveals a Multi-Signaling Regulation of Fas by Tyrosine Phosphorylation and its Implication in Human Cancers.

Authors:  Krittalak Chakrabandhu; Sébastien Huault; Jérôme Durivault; Kévin Lang; Ly Ta Ngoc; Angelique Bole; Eszter Doma; Benoit Dérijard; Jean-Pierre Gérard; Michel Pierres; Anne-Odile Hueber
Journal:  PLoS Biol       Date:  2016-03-04       Impact factor: 8.029

Review 8.  CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases.

Authors:  Matthieu Le Gallo; Amanda Poissonnier; Patrick Blanco; Patrick Legembre
Journal:  Front Immunol       Date:  2017-09-27       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.